Table 3. Multivariate analysis of survival for patients stratified by clinical stage.
| Endpoint | Variable | I/II | III/IV | ||
|---|---|---|---|---|---|
| HR (95%CI) | p | HR (95%CI) | p | ||
| OS | Leukocyte | ||||
| >10 vs ≤10 | 1.48 (0.83–2.63) | 0.185 | 1.39 (1.13–1.71) | 0.002 | |
| continuous | 1.06 (0.97–1.16) | 0.176 | 1.05 (1.01–1.08) | 0.006 | |
| Neutrophil | |||||
| >8 vs ≤8 | 1.23 (0.62–2.44) | 0.548 | 1.73 (1.59–1.89) | <0.001 | |
| continuous | 1.06 (0.96–1.17) | 0.241 | 1.07 (1.03–1.11) | <0.001 | |
| PFS | Leukocyte | ||||
| >10 vs ≤10 | 1.55 (1.03–2.33) | 0.036 | 1.21 (1.01–1.44) | 0.037 | |
| continuous | 1.06 (0.99–1.13) | 0.061 | 1.03 (1.01–1.06) | 0.032 | |
| Neutrophil | |||||
| >8 vs ≤8 | 1.43 (0.90–2.26) | 0.127 | 1.29(1.07–1.56) | 0.009 | |
| continuous | 1.08 (1.01–1.16) | 0.02 | 1.05 (1.02–1.08) | 0.003 | |
| LRFS | Leukocyte | ||||
| >10 vs ≤10 | 1.31 (0.71–2.45) | 0.39 | 0.92 (0.66–1.27) | 0.594 | |
| continuous | 1.05 (0.97–1.15) | 0.23 | 1.01 (0.96–1.05) | 0.748 | |
| Neutrophil | |||||
| >8 vs ≤8 | 1.17 (0.57–2.40) | 0.672 | 0.95 (0.66–1.36) | 0.756 | |
| continuous | 1.08 (0.99–1.19) | 0.095 | 0.99 (0.95–1.05) | 0.908 | |
| DMFS | Leukocyte | ||||
| >10 vs ≤10 | 1.80 (0.98–3.31) | 0.059 | 1.16 (0.91–1.47) | 0.237 | |
| continuous | 1.05 (0.95–1.16) | 0.292 | 1.01 (0.98–1.05) | 0.464 | |
| Neutrophil | |||||
| >8 vs ≤8 | 1.84 (0.95–3.55) | 0.07 | 1.03 (0.99–1.07) | 0.101 | |
| continuous | 1.10 (0.99–1.22) | 0.071 | 1.24 (0.96–1.61) | 0.099 | |
HR: unadjusted hazard ratio; CI: confidence interval; OS: overall survival; PFS: progression-free survival; LRFS: locoregional relapse-free survival; DMFS: distant metastasis-free survival.
Multivariate analyses adjusted for age group (≤45 and >45 years-old), gender, T-classification (T1/T2/T3/T4), N-classification (N0/N1/N2/N3), Pathological types, type of radiotherapy and type of chemotherapy.